Home » Topics » BioWorld Science

BioWorld Science
RSS

New trials evaluate IPI-549 in combination therapies for solid tumors

Sep. 5, 2019

Gilead Sciences initiates phase Ib/II study of GS-4224 in advanced solid tumors

Sep. 5, 2019

CellCentric initiates phase I/IIa study of CCS-1477 in hematological malignancies

Sep. 5, 2019

Applied Therapeutics begins phase III study of AT-1001 for diabetic cardiomyopathy

Sep. 5, 2019

European Commission approves Stelara for moderate to severely active ulcerative colitis

Sep. 5, 2019

Tonix begins phase I study of TNX-601 for daytime treatment of PTSD

Sep. 5, 2019

First safety data presented from phase II trial of revacept

Sep. 5, 2019

Idera Pharmaceuticals and Abbvie to collaborate on immunooncology trial

Sep. 5, 2019

Optimized liver-directed gene therapy for Pompe's disease evaluated in vivo

Sep. 5, 2019

New CDK7 inhibitors presented by Ancureall Biomedical Technology (Shanghai)

Sep. 5, 2019

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 24, 2026.
4D Nucleome opens new wave of gene regulation research, discovery
BioWorld
After a decade of research, the NIH 4D Nucleome program on July 23 delivered a wealth of new insights into how spatial changes in chromatin structure and DNA...
Other news to note for July 22, 2026
BioWorld
Biopharma and med-tech happenings, including deals and partnerships, and other news in brief: Akari, Ashlins, Azurity, Eli Lilly, Engitix, Forge Biologics,...
Brain-penetrant NLRP3 inhibitor shows promise in Parkinson’s
BioWorld Science
Researchers from Changchun Genescience Pharmaceuticals Co. Ltd. described the discovery and preclinical profile of an NLRP3 inhibitor with favorable brain...
GSK’s newly acquired Jideytro wins FDA nod in NSCLC
BioWorld
About a week after closing its $10.6 billion acquisition of Nuvalent Inc., GSK plc has reaped the first reward, announcing U.S. FDA approval of zidesamtinib in...